Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis (STEFOG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02693366
Recruitment Status : Unknown
Verified June 2017 by Marcelo Marcos Morales, Universidade Federal do Rio de Janeiro.
Recruitment status was:  Active, not recruiting
First Posted : February 26, 2016
Last Update Posted : June 6, 2017
Sponsor:
Collaborators:
Ministry of Science and Technology, Brazil
Ministry of Health, Brazil
National Research Council, Brazil
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Information provided by (Responsible Party):
Marcelo Marcos Morales, Universidade Federal do Rio de Janeiro

Brief Summary:
The purpose of this study is to analyze the safety, renal function, metabolic disorders and quality of life data in patients with focal segmental glomerulosclerosis treated with endovascular infusion of bone marrow derived mononuclear cells.

Condition or disease Intervention/treatment Phase
Glomerulosclerosis, Focal Segmental Renal Insufficiency, Chronic Biological: Autologous Cell Transplantation Phase 1

Detailed Description:

Will be studied five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.

Bone marrow aspiration and subsequent cell preparation were accomplished on the same day as the endovascular infusion of autologous Bone Marrow derived Mononuclear stem cells (BMDMCs) in both renal arteries. Collection was performed under spinal anesthesia and light sedation, through puncture and repeated aspirations at the posterior iliac crest region. A total of 80 mL of bone marrow aspirate was collected from each patient, and after removal of bone and fatty residues, mononuclear cells were isolated by a Ficoll-Paque Plus (Amersham Biosciences, São Paulo, Brazil).For each patient, 2×107 cells will be labeled with 99mTc. Briefly, 500 μl of sterile SnCl2 solution is added to the cells and the mixture is incubated at room temperature for 10 min. Forty-five millicurie (mCi) of 99mTc is then added and incubation continued for another 10 min. After centrifugation (500×g for 5 min), the supernatant is removed and the cells are washed in saline solution. The pellet will be also resuspended in saline solution. Viability of the labeled cells will be assessed by the trypan blue exclusion test, and estimated to be greater than 93% in all cases.The labeling efficiency (%) will be calculated by the activity in the pellet divided by the sum of the radioactivity in the pellet plus supernatant and estimated to be greater than 90% in all cases.

After the collection of the stem cells, the patient will be submitted to puncture the femoral artery using the Seldinger technique under local anesthesia, followed by catheterization of the ostium of the renal arteries with minimum use of nonionic iodinated contrast. With the routing of diagnostic catheter or guide, the solution numbering about 30 to 100 million of dissolved plasma cells will be divided and injected into two renal arteries. The infusion volume is about 5 ml in each kidney. Whole body and planar scans will be performed 2 and 24h after infusion to determine the migration and cell viability. The patient will remain hospitalized for more 48 hours for clinical monitoring and collection of laboratorial tests.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety Study of the Endovascular Infusion of Bone Marrow Derived Mononuclear Cells in Patients With Focal Segmental Glomerulosclerosis
Study Start Date : June 2015
Estimated Primary Completion Date : February 2018
Estimated Study Completion Date : March 2018


Arm Intervention/treatment
Experimental: Autologous Cell Transplantation
We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
Biological: Autologous Cell Transplantation
Endovascular infusion of bone marrow derived cells in both renal arteries.




Primary Outcome Measures :
  1. Kidney injury [ Time Frame: 9 months ]

    Increase of serum creatinine of about 0.5 mg / dL when levels are less than 3.0 mg / dl and 1.0 mg / dl baseline levels when are greater than or equal to 3.0 mg / dL) when confirmed with the second examination.

    • Acute: evaluated within 15 days of cell therapy;
    • Subacute: evaluated 15-90 days of cell therapy

  2. Chronic kidney disease [ Time Frame: 9 months ]
    Doubling of serum creatinine based on the third month after the cell therapy or the need to start dialysis

  3. Potential differentiation disorders of transplanted cells [ Time Frame: 9 months ]
    Analyzed by clinical and imaging tests such abdominal ultrasound and chest radiography

  4. Systemic inflammatory potential of mononuclear cells administration in renal circulation [ Time Frame: 9 months ]
    Laboratory tests: C-reactive protein, erythrocyte sedimentation rate, blood count and urinary sediment

  5. Death [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Renal function [ Time Frame: 9 months ]
    The estimated creatinine clearance assessment by MDRD formula

  2. Bone metabolism [ Time Frame: 9 months ]
    Evaluation of bone metabolism by serum phosphorus (mg/dL), calcium (mg/dL), parathormone (pg/ml), 25 (OH) vit. D (ng/ml).

  3. Balance assessment electrolyte and acid-base [ Time Frame: 9 months ]
    Balance assessment electrolyte and acid-base by serum sodium (mEq/l), potassium (mEq/l), uric acid (mg/dl) and bicarbonate

  4. The lipid profile assessment and anemia [ Time Frame: 9 months ]
    The lipid profile assessment (LDL- cholesterol, HDL-cholesterol and triglyceride) and anemia measured by hemoglobin (g/dL) and hematocrit.

  5. Quality of life questionnaire [ Time Frame: 9 months ]
    Clinical improvement of the patient, with subjective assessment of general health and well being through SF36 quality of life questionnaire

  6. Imaging tests [ Time Frame: 9 months ]
    Imaging tests: Renal scintigraphy with 99mTc-DTPA and DMSA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with diagnosis of primary focal segmental glomerulosclerosis after having been previously treated with corticosteroids and immunosuppressive drugs and have not reached satisfactory answer. Will also be considered candidates those patients who performed late diagnosis and therefore no more clinical indication to perform therapy with corticosteroids and immunosuppressants. In both cases, showing irreversible loss of renal function with filtration rate between 40 - 20 ml/min.
  • Patient should use the classical nephroprotective medication: angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, or both.

Exclusion Criteria:

  • Acute urinary tract infection;
  • Urinary infection with tuberculosis bacillus or fungi;
  • Patients with poorly anatomical formations of the urinary tract, polycystic kidney disease and other congenital or acquired kidney diseases.
  • Blood pressure greater than 160 mm Hg systolic and 100 mmHg diastolic, in measurements taken during the last 3 outpatient visits;
  • Who has performed examination with iodinated contrast the last 3 months
  • Use of potentially nephrotoxic drugs;
  • Use of corticosteroid therapy in immunosuppressive doses or more than 0.3 mg/kg/day
  • Inability to obtain vascular access for endovascular procedure
  • Sepsis (defined according to the Society of Critical Care Medicine, American College of Chest Physicians, 1992);
  • Malignancies
  • Autoimmune disorders,
  • Neurodegenerative diseases;
  • Acute heart failure or decompensated;
  • Primary hematologic diseases;
  • Osteopathies reflecting increased risk for spinal puncture;
  • Coagulopathies;
  • Liver failure;
  • History of stroke or myocardial infarction in the last 6 months;
  • Pregnancy or breastfeeding;
  • History and serology of chronic infectious diseases, including HIV, Hepatitis C virus, Hepatitis B virus
  • Participation in another clinical trial last year
  • Cognitive impairment to understand all procedures
  • Prolonged travel plans or domicile changes to other states that generate unable to attend the follow-up visits;
  • Any other clinically significant active disease in the opinion of the principal investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02693366


Locations
Layout table for location information
Brazil
Universitary Hospital Clementino Fraga Filho - UFRJ
Rio de Janeiro, Brazil, 21941913
Sponsors and Collaborators
Universidade Federal do Rio de Janeiro
Ministry of Science and Technology, Brazil
Ministry of Health, Brazil
National Research Council, Brazil
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Investigators
Layout table for investigator information
Principal Investigator: Marcelo Marcos Morales, MD,PHD Universidade Federal do Rio de Janeiro

Layout table for additonal information
Responsible Party: Marcelo Marcos Morales, MD, PhD, Universidade Federal do Rio de Janeiro
ClinicalTrials.gov Identifier: NCT02693366     History of Changes
Other Study ID Numbers: CAAE:01498412.5.0000.5257
First Posted: February 26, 2016    Key Record Dates
Last Update Posted: June 6, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Marcelo Marcos Morales, Universidade Federal do Rio de Janeiro:
bone marrow cells, stem cells, cell therapy
Glomerulosclerosis, Focal Segmental
Renal Insufficiency, Chronic

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Renal Insufficiency, Chronic
Glomerulosclerosis, Focal Segmental
Kidney Diseases
Urologic Diseases
Glomerulonephritis
Nephritis